Pharmaceutical

Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy

Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye drops solution) for patients with dry eye disease (DED) in Europe.

Oct 4, 2024 - 04:00
Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy
Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye drops solution) for patients with dry eye disease (DED) in Europe.
Read the original article

Tags:

Previous Article

ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer

Next Article

Gilead signs agreements to facilitate access to HIV prevention drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill

STAT+: Pharmalittle: Lilly wins FDA approval for a weig...

Nov 9, 2023

Cystic fibrosis: global clinical trials landscape and treatments

Cystic fibrosis: global clinical trials landscape and t...

May 25, 2024

Generate:Biomedicines and Novartis link on protein therapeutics development

Generate:Biomedicines and Novartis link on protein ther...

Sep 26, 2024